ALK and non-small cell lung carcinoma: Sixty patients with ALK-positive NSCLC who received conteltinib were assessable for efficacy due to 3 patients withdrawing the consent (1 patient of 450 mg QD cohort in dose-escalation phase, 1 patient of 800 mg QD cohort in dose-escalation phase, and 1 patient of 300 mg BID cohort in dose-expansion phase) and 1 patient of 100 mg QD cohort in dose-escalation phase experiencing short dosing time.